Table 4.
Current clinical trials of CAR-NK registered on ClinicalTrials.Gov
| NCT number | Cancer type | NK source | Target | CAR structure | Country | Phase | Initial year | State |
|---|---|---|---|---|---|---|---|---|
| NCT04639739 | non-Hodgkin lymphoma | Unknown | CD19 | Unknown | China | Early phase 1 | 2020/11 | Not recruited |
| NCT03692637 | Epithelial ovarian cancer | PB-NK | Mesothelin | Unknown | China | Early phase 1 | 2018/10 | Not recruited |
| NCT03692663 | Castration-resistant prostate cancer | Unknown | PSMA | Unknown | China | Early phase 1 | 2018/10 | Not recruited |
| NCT03692767 | Refractory B-cell Lymphoma | Unknown | CD22 | Unknown | China | Early phase 1 | 2018/10 | Not recruited |
| NCT03690310 | Refractory B-cell lymphoma | Unknown | CD19 | Unknown | China | Early phase 1 | 2018/10 | Not recruited |
| NCT03824964 | Refractory B-cell lymphoma | Unknown | CD19/CD22 | Unknown | China | Early phase 1 | 2019/1 | Unknown |
| NCT03415100 | NKG2D-ligand expressing solid cancer(metastatic solid tumors) | PB-NK | NKG2D-L |
ScFv-CD8aTM-CD3ζ ScFv-CD8aTM-DAP12 |
China | Phase 1 | 2018/1 | Recruited |
| NCT00995137 | B-ALL | PB-NK | CD19 | ScFv-CD8aTM-CD137-CD3ζ | USA | Phase 1 | 2009/10 | Completed |
| NCT03383978 | Glioblastoma | NK-92 | Her2 | ScFv-CD28-CD3ζ | Germany | Phase 1 | 2017/12 | Recruited |
| NCT04245722 | B-cell lymphoma or chronic lymphocytic leukemia | iPSC (FT596) | CD19 | scFv-NKG2D-2B4-CD3ζ-IL-15/R-hnCD16 | USA | Phase 1 | 2020/1 | Recruited |
| NCT03940833 | Multiple myeloma | NK-92 | BCMA | Unknown | China | Phase1/Phase 2 | 2019/5 | Recruited |
| NCT03940820 | ROBO1 expression in solid tumor | NK-92 | ROBO1 | Unknown | China | Phase1/Phase 2 | 2019/5 | Recruited |
| NCT02944162 | CD33 + acute myeloid leukemias | NK-92 | CD33 | ScFv-CD28-CD137-CD3ζ | China | Phase1/Phase 2 | 2016/10 | Completed |
| NCT02742727 | Leukemia and lymphoma | NK-92 | CD7 | ScFv-CD28-4-1BB-CD3ζ | China | Phase1/Phase 2 | 2016/4 | Recruited |
| NCT03579927 | B-cell lymphoma | Cord blood | CD19 | CD19-CD28-zeta-2A-iCasp9-IL15 | USA | Phase1/Phase 2 | 2018/7 | Withdrawn |
| NCT02839954 | MUC1 positive relapsed or refractory solid tumor | NK-92 | MUC1 | ScFv-CD28-4-1BB-CD3ζ | China | Phase1/Phase 2 | 2016/7 | Unknown |
| NCT02892695 | Lymphoma, leukemias | NK-92 | CD19 | ScFv-CD28-4-1BB-CD3ζ | China | Phase1/Phase 2 | 2016/9 | Unknown |
| NCT03056339 | B-cell lymphoma | Cord blood | CD19 | iCasp9-ScFv-CD28-CD3ζ-IL-15 | USA | Phase1/Phase 2 | 2017/2 | Recruited |
| NCT03941457 | Pancreatic cancer | NK-92 | ROBO1 | Unknown | China | Phase1/Phase 2 | 2019/5 | Recruited |
| NCT05410717 | Claudin6 expressed solid tumor | PB-NK | Claudin6 | Unknown | China | Phase1/Phase 2 | 2022/6 | Recruited |
| NCT05213195 | Colorectal Cancer | Unknown | NKG2D-L | Unknown | China | Phase 1 | 2021/12 | Recruited |
| NCT05008536 | Multiple Myeloma | Cord blood | BCMA | Unknown | China | Early phase 1 | 2021/10 | Recruited |
| NCT05247957 | NKG2DL expressed AML | Cord blood | NKG2D-L | Unknown | China | Phase 1 | 2021/10 | Recruited |
| NCT05215015 | AML | Unknown | CD33/CLL1 | Unknown | China | Early phase 1 | 2021/11 | Recruited |
| NCT05008575 | AML | Unknown | CD33 | Unknown | China | Phase 1 | 2021/12 | Recruited |
| NCT05194709 | Advanced Solid Tumors | Unknown | 5T4 | Unknown | China | Early phase 1 | 2021/12 | Recruited |
| NCT04887012 | B-cell NHL | PB-NK | CD19 | Unknown | China | Phase 1 | 2021/05 | Recruited |
| NCT05020678 | B-cell malignancies | PB-NK | CD19 | CD19ScFv-CD8aTM-OX40-CD3ζ-T2A-IL15 | USA | Phase 1 | 2021/08 | Recruited |
| NCT04847466 | Gastric or Head and Neck Cancer | NK-92 | PD-L1 | Unknown | USA | Phase 2 | 2021/12 | Recruited |
| NCT04623944 | AML or MDS | PB-NK | NKG2D-L | ScFv-CD8aTM-OX40-CD3ζ-T2A-IL15 | USA | Phase 1 | 2020/09 | Recruited |
| NCT05410041 | B-cell malignancies | PB-NK | CD19 | Unknown | China | Phase 1 | 2022/05 | Recruited |
| NCT05182073 | Multiple Myeloma | iPSC (FT576) | BCMA | scFv-NKG2D-2B4-CD3ζ-IL-15/R-hnCD16 | USA | Phase 1 | 2021/11 | Recruited |